Ningbo Menovo Pharmaceutical Co (SHSE:603538) ROCE %: 5.93% (As of Mar. 2026)


SHSE:603538 Ningbo Menovo Pharmaceutical Co Ltd SHSE:603538
62 GF Score
Price ¥38.81
GF Value ¥22.26
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Ningbo Menovo Pharmaceutical Co ROCE %?

Ningbo Menovo Pharmaceutical Co SHSE:603538 -1.47% 62 ROCE % is 5.93% as of Mar. 2026. GuruFocus rates SHSE:603538 with a GF Score™ of 62/100 and a GF Value™ of ¥22.26 (Significantly Overvalued). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Ningbo Menovo Pharmaceutical Co's annualized ROCE % for the quarter that ended in Mar. 2026 was 5.93%.

Ningbo Menovo Pharmaceutical Co  (SHSE:603538) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Ningbo Menovo Pharmaceutical Co ROCE % Related Terms

Ningbo Menovo Pharmaceutical Co ROCE % Historical Data

* Premium members only.

The historical data trend for Ningbo Menovo Pharmaceutical Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ningbo Menovo Pharmaceutical Co ROCE % Chart

Ningbo Menovo Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.55 13.92 1.21 4.43 5.42

Ningbo Menovo Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.16 6.53 8.72 1.79 5.93
SHSE:603538
62GF Score
Ningbo Menovo Pharmaceutical Co Ltd SHSE:603538
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ningbo Menovo Pharmaceutical Co ROCE % Calculation

Ningbo Menovo Pharmaceutical Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=171.609/( ( (4651.221 - 1585.961) + (4852.376 - 1584.276) )/ 2 )
=171.609/( (3065.26+3268.1)/ 2 )
=171.609/3166.68
=5.42 %

Ningbo Menovo Pharmaceutical Co's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=191.252/( ( (4852.376 - 1584.276) + (4597.7 - 1414.517) )/ 2 )
=191.252/( ( 3268.1 + 3183.183 )/ 2 )
=191.252/3225.6415
=5.93 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 5.93% mean?
Ningbo Menovo Pharmaceutical Co (SHSE:603538) has a ROCE % of 5.93% as of Mar. 2026.
Is Ningbo Menovo Pharmaceutical Co's ROCE % too high?
Ningbo Menovo Pharmaceutical Co's current ROCE % is 5.93%. The Drug Manufacturers industry median ROCE % is 7.03. Ningbo Menovo Pharmaceutical Co's value of 5.93% is 15.6% below this industry median. Overall, Ningbo Menovo Pharmaceutical Co has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ningbo Menovo Pharmaceutical Co's ROCE % compare to ZTS and UTHR?
Ningbo Menovo Pharmaceutical Co's ROCE % of 5.93% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.03. Ningbo Menovo Pharmaceutical Co's value of 5.93% is 15.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.03, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ningbo Menovo Pharmaceutical Co's current ROCE % of 5.93% is 15.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ningbo Menovo Pharmaceutical Co's current ROCE % is 5.93%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ningbo Menovo Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Ningbo Menovo Pharmaceutical Co (SHSE:603538) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥22.26, compared to a current price of ¥38.81 — trading 74.3% above its estimated fair value. The current ROCE % is 5.93% and 15.6% below the Drug Manufacturers industry median of 7.03. Ningbo Menovo Pharmaceutical Co's overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Ningbo Menovo Pharmaceutical Co (SHSE:603538), the current ROCE % is 5.93% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ningbo Menovo Pharmaceutical Co (SHSE:603538) Overvalued in 2026?

Based on GuruFocus' analysis, Ningbo Menovo Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥38.81 is trading 74.3% above its estimated GF Value™ of ¥22.26. GuruFocus considers Ningbo Menovo Pharmaceutical Co to be Significantly Overvalued.

Key valuation signals for SHSE:603538:

  • ROCE %: 5.93%
  • GF Value™: ¥22.26 vs. price of ¥38.81 (74.3% above fair value)
  • GF Score™: 62/100 with 6 warning signs
  • Industry Position: 15.6% below the Drug Manufacturers median

No single metric tells the full story. See the SHSE:603538 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ningbo Menovo Pharmaceutical Co Business Description

Address No.999,Yangfan Road, Room 1406, No.1, High-tech Zone, Ningbo, CHN, 315040
Ningbo Menovo Pharmaceutical Co Ltd is a China-based company is engaged in the research and development, pilot, production and sales of pharmaceutical intermediates, APIs and finished drugs. Its products line includes cardiovascular, central nervous, respiratory, anti-tumor, anti-infective, digestive system, geriatric diseases and anti-viral systems.
62GF Score

Get the complete analysis for SHSE:603538

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥38.81
Price
¥22.26
GF Value